BioCurex Inc. Release: RECAF Test Detects Lung, Breast and Gastrointestinal Cancers Using a Drop of Saliva-Work Done in Collaboration with the Goshen Center for Cancer Care

RICHMOND, BRITISH COLUMBIA--(Marketwire - October 03, 2008) - BioCurex Inc. (OTCBB: BOCX) today announced results showing that its RECAF test can detect cancer with high sensitivity and specificity using a small sample of saliva. The work was done as part of an ongoing collaboration with the Goshen Center for Cancer Care in Indiana.